At this stage, mechanism remains speculative
It is a GLP-1 agonist like the other medications in this chapter, and also a glucose-dependent insulinotropic polypeptide (GIP) agonist
Obesity, binge eating, and metabolic syndrome frequently coexist with anxiety, depression, and chronic stress, yet most metabolic therapies target peripheral pathways while neglecting central drivers of behavior
By developing this in-depth understanding of the impacts of the GLP-1s on patient populations, treatment paradigms and clinician messaging, MedTech companies will be able to make informed strategic decisions to stay the course or pivot to other promising segments if needed
Retatrutide is drawing interest because it extends that concept further by adding glucagon receptor activity to GLP-1 and GIP
Clients should contact analysts and execute transactions through a J.P